Primary regulatory
FDA Approves Zepbound (Tirzepatide) for Chronic Weight Management
FDA approval of Zepbound (tirzepatide) injection for chronic weight management, NDA 217806.
U.S. Food and Drug AdministrationPublished 2023-11-08Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-zepbound-approval-2023
Source usage
Linked from 11 pages
Compound
Tirzepatide
ComparisonRetatrutide vs Tirzepatide
ComparisonSemaglutide vs Tirzepatide for Weight Loss
ComparisonTirzepatide vs Semaglutide
Evidence curationBest Peptides for Weight Loss
GuideCompounded GLP-1 Regulation: What Changed and What to Check
GuideFDA Enforcement Timeline: Major Actions on Peptides and Compounding
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
GuidePeptide Half-Life Reference Table
GuidePeptide Terminology Glossary
Research hubCompounded Peptides Explained: 503A vs 503B
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.